■ Completed the formal signing of an external financing agreement totaling 3 billion CNY and introduced a number of well-known strategic investors including Gaochun Capital, CPE, Beilin Capital, Yuanyi Investment and E Fund Capital.

■ It will usher MicroPort^® MedBot into a new stage of rapid development on a global scale and promote the popularization of various surgical robots to benefit more ordinary patients.

Shanghai, China --- On August 31, 2020, MicroPort^® Scientific Corporation (hereinafter referred to as "Microport^®”) and its subsidiary MicroPort^® (Shanghai) Medbot Co., Ltd. (hereinafter referred to as "Microport^® Medbot”) jointly completed the formal signing of an external financing agreement totaling 3 billion CNY, including a direct capital increase of 1.5 billion CNY to the latter and an equity transfer of 1.5 billion CNY from Microport^®, and introduced a number of well-known strategic investors including Gaochun Capital, CPE, Beilin Capital, Yuanyi Investment and E Fund Capital. After the completion of this round of financing, MicroPort^® MedBot is still a subsidiary of Microport^®.

Since MicroPort^® MedBot was established in 2014, it has been dedicated to providing integrated intelligent surgical solutions that can save patients' lives or improve their quality of life. After years of R&D, innovation and industrial accumulation, it has developed into a group operation company that has mastered the base technology of the whole chain of surgical robots, with multidisciplinary integration and platform expansion capabilities including optics, mechanics, electricity, control, software, calculation and imaging, and its business covers five "Golden Racetracks": endoscopic, orthopedic, panvascular, natural lumen and percutaneous puncture fields. The Company has developed three flagship products: DFVision^® 3D Electronic Laparoscopic System, Toumai^® Laparoscopic Surgical Robot and Honghu ^®Honghu Orthopedic Surgical Robot (also known as "joint replacement surgery robot"), have all entered the "Green Path" of innovative medical devices in National Medical Products Administration. The company has built up a global team of outstanding talents with rich experience in robot R&D and industrialization of medical devices, with more than 250 patents at home and abroad, and has established a complete independent intellectual property system in the field of surgical robots. It is a hi-tech cultivation enterprise of Shanghai, a contractor of the project of Shanghai Engineering Center for Minimally Invasive Surgical Robotics, and a pilot enterprise of patent work of Shanghai.

The structural program of high-resolution imaging objective lens and electronic mirror independently developed for DFVision^® 3D Electronic Laparoscopic System abandons the huge optical mechanism of traditional laparoscope, which not only accurately presents the anatomical level of human organs to meet the operator's demand for accurate identification of tissue details, but also significantly optimizes the operator's operating experience. The laparoscopic cholecystectomy was completed in Run Run Shaw Hospital affiliated to Zhejiang University School of Medicine on October 21, 2019.

Toumai^® is an independently developed endoscopic surgery robot system. It completed the "Golden Standard” surgery of radical prostatectomy, first of its kind, at the Oriental Hospital affiliated to Tongji University on November 01, 2019. It is a highly flexible wrist surgical system. Its 3D endoscopic system provides a stereoscopic and real surgical vision, and its intuitive master-slave teleoperation is sensitive and easy to use. Thanks to its extremely high clinical advantages, the operation is simplified, and the time of operation is shortened.

Honghu Orthopedic Surgical Robot (also known as "joint replacement surgery robot") has a complete base core technology, which provides a solution to the long-existing clinical problems through precise bone resection, precise implant of prosthesis, calibration and elimination of human error and standardized postoperative effect. The first case of its clinical trial on human body was completed in the Ninth People's Hospital affiliated to Shanghai Jiaotong University School of Medicine on June 30, 2020. The application for registration and approval by the Food and Drug Administration (FDA) of the United States has been initiated for this product, as lays a foundation for opening up the American market.

Shanghai Microport^® Medbot (Group) Co., Ltd. made quick response to the clinical needs during the epidemic this year, and its bronchial surgery robot independently developed for the diagnosis and treatment of novel coronavirus (hereinafter referred to as "COVID-19") completed its first robot-assisted bronchoscopic alveolar lavage in the Chest Hospital affiliated to Shanghai Jiaotong University. The System’s teleoperation achieved physical isolation between the healthcare staffs and the surgical infection environment, which could not only reduce the risks of infection during the diagnosis and treatment but also help increase the diagnosis accuracy and cure rates of COVID-19.

MicroPort^® MedBot has actively launched strategic cooperation around the world to build a global innovation platform with deep integration of technical R&D with the industry. It concluded a strategic cooperation agreement with Robocath, a French vascular interventional robot company, in April 2020, and jointly established a joint venture in China to produce and assemble robot systems in China and develop the next generation robot systems and related AI technologies. This will accelerate the introduction of vascular interventional robot products into the Chinese market.

In May 2020, it reached a strategic cooperation agreement with NDR Medical Technology (hereinafter referred to as "NDR") of Singapore and jointly established a joint venture in China, dedicated to the distribution, manufacturing and joint R&D of "NDR" products in Great China area. The percutaneous puncture robot developed by NDR can be applied to percutaneous lung biopsy and percutaneous nephrolithotomy. The cooperation will further accelerate the layout of the Company in the field of percutaneous puncture robotics.

With the continuous maturity of the global surgical robot industry, the surgical robot market shows a rapid growth trend. It is the maturest time for commercialization of endoscopic surgical robots and the revenue of single kind of product accounts for more than 87% of the overall industry of surgical robots. The cumulative installed capacity of the world exceeds 5,600 sets, and the annual quantity of surgical cases exceeds 1 million. Joint replacement surgical robot has become the next large-scale commercial surgical robot product, and its installed capacity of the world has exceeded 1,000 sets. The market of surgical robots in the fields of vascular intervention, natural lumen, percutaneous puncture, etc. is also in a rapid cultivation process. According to data from Global Market Insight, the global market for surgical robots will grow at a compound annual growth rate of 24.4% from 2018 to 2024, and the market size is expected to reach 130 billion CNY in 2024.

Dr. He Chao, the General Manager of MicroPort^® MedBot said:"After years of painstaking development, MicroPort^® MedBot has developed into a platform innovation company of multidisciplinary surgical robot solutions with a global layout. The introduction of this round of strategic partners will bring more resources for the higher-level R&D, production and future industrial expansion of the Company. We believe that with the company's main products marketized one after another, it will provide integrated intelligent surgical solutions for treating more diseases that are threatening the human health."

Sun Hongbin, the chairman of MicroPort^® MedBot said:"Surgical robot has important strategic significance in remote control, precise, minimally invasive, personalized and intelligent operation. The present round of financing will bring necessary financial support to the steady marketization, large-scale industrialization and market promotion of the company's surgical robot products. Moreover, with the Group's strong technological innovation, business collaboration ability and global market and academic resources, especially the modern enterprise control system introduced after new shareholders join in, MicroPort^® MedBot will enter a new stage of rapid development on a global scale, and promote the popularization of various surgical robots to benefit more patients."